{"id":"tak-861","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL5840837","moleculeType":null,"molecularWeight":"417.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TAK-861 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism of action is particularly beneficial for patients with type 2 diabetes, as it helps to lower HbA1c levels and improve glycemic control.","oneSentence":"TAK-861 is a selective, reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:19.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07363720","phase":"PHASE3","title":"A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-29","conditions":"Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy","enrollment":88},{"nctId":"NCT05816382","phase":"PHASE2, PHASE3","title":"A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-04-05","conditions":"Narcolepsy Type 1","enrollment":500},{"nctId":"NCT06505031","phase":"PHASE3","title":"A Study of TAK-861 in People With Narcolepsy Type 1","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-10-08","conditions":"Narcolepsy Type 1","enrollment":105},{"nctId":"NCT06470828","phase":"PHASE3","title":"A Study of TAK-861 for the Treatment of Narcolepsy Type 1","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-07-02","conditions":"Narcolepsy Type 1","enrollment":168},{"nctId":"NCT05687903","phase":"PHASE2","title":"A Study of TAK-861 in Participants With Narcolepsy Type 1","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-01-09","conditions":"Narcolepsy Type 1","enrollment":112},{"nctId":"NCT05687916","phase":"PHASE2","title":"A Study of TAK-861 in Participants With Narcolepsy Type 2","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-01-09","conditions":"Narcolepsy Type 2","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAK-861","genericName":"TAK-861","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-861 is a selective, reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}